Health systems' rare rejection of Alzheimer's drug sparks questions about FDA approvalsHealth systems' rare rejection of Alzheimer's drug sparks questions about FDA approvalsHealth systems' rare rejection of Alzheimer's drug sparks questions about FDA approvals

Health systems' rare rejection of Alzheimer's drug sparks questions about FDA approvals

Medical centers declining to administer an FDA-approved drug is rare, and controversy surrounding the Alzheimer's drug Aduhelm has led to questions about the approval process, and even value-based care.

from Section Page News - Modern Healthcare https://ift.tt/2UnK1SR